IGFBP-3 Test

Your body runs a tightly regulated growth and repair system powered by growth hormone, and IGFBP-3 (insulin-like growth factor binding protein 3) is its most abundant carrier protein in the blood. When IGFBP-3 drops too low, large studies consistently link it to higher rates of death from heart disease and other causes. When it runs too high, it has been tied to increased risk of type 2 diabetes and certain cancers. Knowing where you fall gives you a window into how well this system is functioning.

IGFBP-3 is produced mostly by liver cells in direct response to growth hormone. It acts like a transport shuttle, binding about 75-90% of the growth factors circulating in your blood and controlling how much of that signal actually reaches your tissues. Because its production tracks so closely with growth hormone output, a single blood draw of IGFBP-3 can tell you something that growth hormone itself cannot: growth hormone spikes and drops throughout the day, making it unreliable in a single sample, while IGFBP-3 stays remarkably stable.

How IGFBP-3 Works in Your Body

Growth hormone travels from your pituitary gland to the liver, where it triggers the production of both IGF-1 (the main growth factor) and IGFBP-3. Once in the bloodstream, IGFBP-3 forms a three-part complex with IGF-1 (or IGF-2) and a stabilizing molecule called the acid-labile subunit (a protein that locks the complex together). This complex extends the lifespan of growth factors from minutes to hours, preventing them from being cleared too quickly by the kidneys.

Beyond just carrying growth factors, IGFBP-3 also acts as a gatekeeper. By holding onto IGF-1, it controls how much free growth factor is available to stimulate cell growth. This dual role, both protecting and restricting growth factor activity, helps explain why IGFBP-3 shows up in research on conditions as different as heart disease and cancer.

Cardiovascular Disease and Mortality

The strongest and most consistent finding across multiple large studies is that low IGFBP-3 predicts a higher risk of dying, particularly from cardiovascular causes. In the Study of Health in Pomerania, which tracked over 4,000 adults for an average of 8.5 years, men with IGFBP-3 below the 10th percentile were about 87% more likely to die from any cause compared to those with normal levels. Women showed a similar but weaker pattern, with a 63% increased risk that did not reach statistical significance.

The Health in Men Study followed nearly 4,000 men aged 70 and older for over five years and found that those in the lowest fifth of IGFBP-3 levels were about 57% more likely to die than those in the highest fifth. This held up even after accounting for traditional cardiovascular risk factors like blood pressure, cholesterol, and smoking, and the association was independent of IGF-1 levels.

Data from the Cardiovascular Health Study in adults 65 and older showed that each standard deviation decrease in IGFBP-3 was associated with about a 12% increase in coronary events over nearly seven years of follow-up. Low IGFBP-3 has also been linked to thicker carotid artery walls, an early structural sign of atherosclerosis, in the Study of Health in Pomerania.

Type 2 Diabetes Risk

While low IGFBP-3 signals cardiovascular danger, higher IGFBP-3 appears to increase diabetes risk, creating a paradox that makes this biomarker especially interesting to track. In the EPIC-Potsdam study of over 2,200 adults, those in the highest quarter of IGFBP-3 had a 33% greater chance of developing type 2 diabetes compared to the lowest quarter. This association held after adjusting for IGF-1, BMI, and other metabolic factors.

The signal was even stronger in women. Among more than 3,100 older adults in the Cardiovascular Health Study followed for 16 years, women in the top third of IGFBP-3 were about 2.3 times as likely to develop diabetes as those in the bottom third. A Mendelian randomization study using genetic data from over 341,000 UK Biobank participants confirmed this was likely a causal relationship: each standard deviation increase in genetically determined IGFBP-3 was associated with a 26% higher odds of type 2 diabetes.

Cancer Associations

The relationship between IGFBP-3 and cancer varies by cancer type, and the evidence points in different directions depending on the population studied. A major meta-analysis of 21 studies found that higher IGFBP-3 was associated with about a 51% increased risk of premenopausal breast cancer. A pooled analysis of 17 prospective studies with nearly 4,700 breast cancer cases found a more modest 23% increased risk in postmenopausal women, though this association largely disappeared after accounting for IGF-1 levels.

For colorectal cancer, a study of over 4,000 older men followed for nine years found that each standard deviation increase in IGFBP-3 was associated with a 20% higher risk, and this association was independent of IGF-1. A collaborative analysis of 20 studies with over 17,000 prostate cancer cases showed a modest 8% increase in risk per standard deviation of IGFBP-3, though this was partly explained by IGF-1 levels.

In contrast, a Japanese cohort study found that participants with higher total IGFBP-3 actually had lower risk of developing any cancer. These conflicting findings likely reflect IGFBP-3's dual biology: it can both suppress tumor growth through direct cellular effects and, as part of the IGF complex, support the growth factor signaling that some cancers exploit.

Growth Hormone Deficiency

The traditional clinical use of IGFBP-3 is diagnosing growth hormone deficiency, especially in children. Because IGFBP-3 production depends directly on growth hormone, persistently low levels strongly suggest the pituitary gland is not producing enough growth hormone. A meta-analysis found IGFBP-3 has 50% sensitivity and 79% specificity for growth hormone deficiency. In practical terms, this means a low IGFBP-3 is a strong confirmatory signal (when it is low, it is almost always real), but a normal reading does not rule the condition out.

In prepubertal children, the test performs better, with sensitivity rising to 60% and specificity reaching nearly 98%. A low IGFBP-3 in a young child has a 90% positive predictive value for abnormal growth hormone stimulation testing. In adults, IGFBP-3 can also help identify growth hormone excess (acromegaly), where 85% of patients with active disease show elevated levels.

Reference Ranges

IGFBP-3 values change substantially across your lifetime. Levels rise from infancy, peak around age 22, plateau between ages 15 and 25, then gradually decline with each decade. After age 60, women tend to have higher levels than men. Any interpretation of your result must account for your age and sex.

Reference ranges also vary significantly between labs because different testing platforms (immunoassays versus newer chemiluminescence methods) can produce different absolute numbers for the same blood sample. The largest normative dataset comes from a multicenter study of nearly 15,000 healthy subjects using the IDS iSYS automated assay. Because of assay variability, comparing your results over time within the same lab is more meaningful than comparing against a single published cutpoint.

For mortality risk stratification, studies have used the 10th percentile as a low cutpoint. Falling below this threshold was associated with substantially increased death risk across multiple populations. There are no consensus "optimal" levels from a longevity perspective, but maintaining levels above the lowest decile for your age and sex appears protective.

The IGFBP-3 Paradox: Mortality vs. Disease Risk

One of the most striking features of this biomarker is that low levels predict death, while higher levels predict diabetes and some cancers. This is not a contradiction. IGFBP-3 sits at a biological crossroads: too little means your growth and repair systems are underperforming (bad for your heart and longevity), while too much means growth factor signaling may be excessively active (which can fuel metabolic dysfunction and cell overgrowth). Research on exceptionally long-lived people (nonagenarians in the Leiden Longevity Study) found that a lower ratio of IGF-1 to IGFBP-3, meaning relatively more IGFBP-3 restraining growth factor activity, was associated with better survival and functional status.

This suggests that the balance between IGF-1 and IGFBP-3, rather than either number in isolation, may be the most informative metric for long-term health. A moderate IGFBP-3 level, high enough to avoid the mortality risk of deficiency but not so high that it tips toward metabolic trouble, appears to be the sweet spot.

Tracking Your Trend

IGFBP-3 is one of the more reliable biomarkers for serial tracking. Its within-person variation is only about 8-10%, and its stability over time is excellent, with an intraclass correlation of 0.88 over roughly two years. That means your IGFBP-3 level today is likely a good approximation of your true baseline, and meaningful changes from that baseline are real, not noise.

Get a baseline measurement and retest in 6 to 12 months. If you are making changes that could affect the growth hormone axis (adjusting exercise intensity, changing body composition, addressing nutritional deficiencies), consider retesting at 3 to 6 months to see if your level is responding. Because IGFBP-3 declines naturally with age, tracking your personal trajectory over years lets you distinguish normal aging from an accelerating decline that might warrant investigation.

Always compare results from the same lab using the same assay. Different testing platforms can give substantially different absolute numbers, which means switching labs between tests can create the appearance of a change that is actually just a measurement difference.

When Results Can Be Misleading

Recent surgery is the single biggest confounder for IGFBP-3. Levels can drop to just 36% of their pre-surgical value within two days of an operation, driven by enzymes that break down the protein. This effect takes four to seven days to resolve. If you have had surgery in the past two weeks, your result is unreliable.

Acute illness, including infections and critical illness, also suppresses IGFBP-3 substantially. Even a bad flu or COVID illness could temporarily lower your level. Wait at least two to three weeks after recovering from any significant illness before testing.

Several common medications shift IGFBP-3 without affecting the underlying biology the test is meant to reflect. Oral contraceptives significantly increase IGFBP-3 (by roughly 0.9 to 1.1 standard deviations), which could mask a genuinely low level. Corticosteroids like prednisone and dexamethasone decrease IGFBP-3 by 30-40% through direct suppression of liver production, not by causing growth hormone deficiency. If you are on either of these medications, mention them when interpreting your results. Transdermal estrogen has minimal effect compared to oral forms.

A brief intense workout can temporarily raise IGFBP-3 by about 23% immediately after exercise. This normalizes quickly, but for the most consistent results, avoid intense exercise in the few hours before your blood draw. Fasting status has minimal impact on IGFBP-3, so you do not need to fast for this test.